Celltrion欧洲高毛利生物类似药份额继续提升

Celltrion's high-margin follow-on product lineup is recording steady growth across Europe.
According to pharmaceutical market research firm IQVIA on the 10th, Omlyclo (active ingredient: omalizumab), a chronic spontaneous urticaria treatment launched in Europe last September as a first-mover biosimilar, recorded a share of about 16% as of the first quarter of this year.
In Spain, one of Europe's five major markets, the product recorded a share of about 71%, establishing itself as a core treatment leading the local omalizumab market just six months after launch. Prescriptions also expanded rapidly in other major European countries, including Portugal (47%), Ireland (41%), and Norway (31%).
Vegzelma (active ingredient: bevacizumab), a treatment for metastatic colorectal cancer and breast cancer, is also maintaining its market influence. Over the same period, Vegzelma recorded a share of about 28% in Europe, holding the top position in the bevacizumab market for 21 consecutive months.
Celltrion's product lineup is also continuing its performance in the autoimmune disease field. Yuflyma (active ingredient: adalimumab) holds the top prescription position in Europe's adalimumab market for a full year with a share of about 22%. Its performance is clearly confirmed across Europe's five major markets with significant market influence, including the United Kingdom (49%) and Italy (46%).
Steqeyma (active ingredient: ustekinumab), a high-margin follow-on product, also recorded a share of about 9% and is continuing its growth every quarter. Prescriptions are expanding in individual countries such as Portugal (41%), Sweden (28%), and Italy (20%), while sales that maximize synergy between product lines, such as bundling with other autoimmune disease products, are also actively taking place.
To maximize the performance of its high-margin product lineup, Celltrion plans to expand local sales personnel and strengthen sales capabilities, while also actively pursuing marketing activities targeting key opinion leader (KOL) groups, including participation in core global conferences such as the European Respiratory Society (ERS) and the United European Gastroenterology Week (UEGW).
Celltrion expects the performance of its high-margin follow-on product lineup to show even steeper growth toward the end of the year, driven by factors that expand second-half sales stemming from the characteristics of the European pharmaceutical market. These include ▲bids in major European countries concentrated in the second and third quarters, ▲initial volume deliveries based on order results, and ▲expanded year-end drug inventory purchases aimed at preparing for the start of the following year.
"As large bids are expected to continue to be held in major countries, we will do our utmost to achieve both sales expansion and performance growth in the second half," a Celltrion official said.